Article Sidebar

Submitted
Jul 24, 2025
Published
Jul 24, 2025
Download
PDF
Statistic
Read Counter : 93 Download : 45

Main Article Content

Abstract

During the study it has been observed that the most common causative agent for both uncomplicated and complicated UTIs is Escherichia coli which is highly resistant to amphicillin, then followed by klebsiella pneumonia, proteusspp, enterobacterspp, enterococcus spp. the most common gram positive bacteria is staphylococcus aureus. Cystitis (infection of bladder) is common among types of UTI.Out of 100 patients 57(57%) were females and 43(43%) were males. Females are more prone to develop UTI due to physiological changes mostly post-menopause patients. During the study males are mainly associated with enlarge prostate. In the study most common symptoms observed were dysuria or burning micturition, fever and urgency. Magnexforte + sulbactam (34.6%) commonly prescribed antibiotic for both uncomplicated and complicated then followed by cephalosporins, macrolides other class of antibiotics. Fluoroquinolones (5%) class of antibiotic particularly prescribed in case of complicated UTI. It has also been observed that amphicillin and TMP-SMX (trimethoprim-sulfamethoxazole) antibiotics is not recommended because of its resistance

Keywords

Complicated and uncomplicated UTI antibiotics Risk factors

Article Details

How to Cite
Azra Anjum, & G. Sudhakara rao. (2025). Study of Prevention and Management of Urinary Tract Infections in Adults in Tertiary Care Hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 14(3), 413-420. Retrieved from https://ijrpp.com/ijrpp/article/view/715
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, Lavi I, Stamm W., Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002 May 01;34(9):1165-9.
  2. 2. Pijl JP, Glaudemans AWJM, Slart RHJA, Kwee TC. 18F-FDG PET/CT in Autosomal Dominant Polycystic Kidney Disease Patients with Suspected Cyst Infection. J Nucl Med. 2018 Nov;59(11):1734-1741.
  3. 3. Wesolek JL, Wu JY, Smalley CM, Wang L, Campbell MJ. Risk Factors for Trimethoprim and Sulfamethoxazole-Resistant Escherichia Coli in ED Patients with Urinary Tract Infections. Am J Emerg Med. 2022 Jun;56:178-182.
  4. 4. Abi Tayeh G, Safa A, Sarkis J, Alkassis M, Khalil N, Nemr E, El Helou E. Determinants of pyelonephritis onset in patients with obstructive urolithiasis. Urologia. 2022 Feb;89(1):100-103.
  5. 5. Young M, Leslie SW. StatPearls. StatPearls Publishing; Treasure Island (FL): Jun 26, 2023. Percutaneous Nephrostomy.
  6. 6. Jouret F, Lhommel R, Devuyst O, Annet L, Pirson Y, Hassoun Z, Kanaan N. Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Nephrol Dial Transplant. 2012 Oct;27(10):3746-51.
  7. 7. Ronsin C, Bailly C, Le Turnier P, Ville S. Value of FDG-PET/CT in monitoring cyst infections in patients with autosomal dominant polycystic renal disease. Clin Kidney J. 2021 Oct;14(10):2273-2275.
  8. 8. Hasan SMM, Salh BS. Emphysematous cystitis as a potential marker of severe Crohn's disease. BMC Gastroenterol. 2022 Apr 11;22(1):181.
  9. 9. Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine (Baltimore). 2007 Jan;86(1):47-53.
  10. 10. Ranjan SK, Navriya SC, Kumar S, Mittal A, Bhirud DP. Emphysematous cystitis: A case report and literature review of 113 cases. Urol Ann. 2021 Jul-Sep;13(3):312-315.
  11. 11. Arrambide-Herrera JG, Robles-Torres JI, Ocaña-Munguía MA, Romero-Mata R, Gutiérrez-González A, Gómez-Guerra LS. Predictive factors for mortality and intensive care unit admission in patients with emphysematous pyelonephritis: 5-year experience in a tertiary care hospital. Actas Urol Esp (Engl Ed). 2022 Mar;46(2):98-105.
  12. 12. Desai R, Batura D. A systematic review and meta-analysis of risk factors and treatment choices in emphysematous pyelonephritis. Int Urol Nephrol. 2022 Apr;54(4):717-736.
  13. 13. Koch GE, Johnsen NV. The Diagnosis and Management of Life-threatening Urologic Infections. Urology. 2021 Oct;156:6-15.
  14. 14. Cui C, Jiang J, Chen W, Cui LG, Wang JR. [Xanthogranulonatous pyelonephritis: report of 5 cases]. Beijing Da Xue Xue Bao Yi Xue Ban. 2018 Aug 18;50(4):743-746.
  15. 15. Werneburg GT. Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects. Res Rep Urol. 2022;14:109-133.
  16. 16. Cruz J, Figueiredo F, Matos AP, Duarte S, Guerra A, Ramalho M. Infectious and Inflammatory Diseases of the Urinary Tract: Role of MR Imaging. Magn Reson Imaging Clin N Am. 2019 Feb;27(1):59-75.
  17. 17. Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018. Open Forum Infect Dis. 2022 Jan;9(1):ofab591.